These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 32086762)
21. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Sun H; England CG; Hernandez R; Graves SA; Majewski RL; Kamkaew A; Jiang D; Barnhart TE; Yang Y; Cai W Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2169-2179. PubMed ID: 27342417 [TBL] [Abstract][Full Text] [Related]
23. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
24. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286 [TBL] [Abstract][Full Text] [Related]
25. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Ehlerding EB; England CG; Majewski RL; Valdovinos HF; Jiang D; Liu G; McNeel DG; Nickles RJ; Cai W Mol Pharm; 2017 May; 14(5):1782-1789. PubMed ID: 28388076 [TBL] [Abstract][Full Text] [Related]
26. PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response. Sun L; Li Z; Ma Y; Ludwig J; Kim HS; Zeng D Biomed Res Int; 2021; 2021():6654262. PubMed ID: 34212037 [TBL] [Abstract][Full Text] [Related]
28. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule. Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877 [TBL] [Abstract][Full Text] [Related]
29. Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFRα) in papillary thyroid cancer using immuno-PET. Wagner M; Wuest M; Hamann I; Lopez-Campistrous A; McMullen TPW; Wuest F Nucl Med Biol; 2018 Mar; 58():51-58. PubMed ID: 29367096 [TBL] [Abstract][Full Text] [Related]
30. Visualization and quantification of Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525 [TBL] [Abstract][Full Text] [Related]
31. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955 [TBL] [Abstract][Full Text] [Related]
32. PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment. Shi S; Orbay H; Yang Y; Graves SA; Nayak TR; Hong H; Hernandez R; Luo H; Goel S; Theuer CP; Nickles RJ; Cai W J Nucl Med; 2015 Jun; 56(6):927-32. PubMed ID: 25883125 [TBL] [Abstract][Full Text] [Related]
33. Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation. Martin S; Wendlinger L; Zitti B; Hicham M; Postupalenko V; Marx L; Giordano-Attianese G; Cribioli E; Irving M; Litvinenko A; Faizova R; Viertl D; Schottelius M EJNMMI Res; 2024 Aug; 14(1):77. PubMed ID: 39196448 [TBL] [Abstract][Full Text] [Related]
34. Preclinical Evaluation of [ Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706 [TBL] [Abstract][Full Text] [Related]
35. Immuno-PET Monitoring of CD8 Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600 [TBL] [Abstract][Full Text] [Related]
36. Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621 [TBL] [Abstract][Full Text] [Related]
37. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Tavaré R; McCracken MN; Zettlitz KA; Knowles SM; Salazar FB; Olafsen T; Witte ON; Wu AM Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1108-13. PubMed ID: 24390540 [TBL] [Abstract][Full Text] [Related]
38. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138 [TBL] [Abstract][Full Text] [Related]
39. TE1PA as Innovating Chelator for Navarro AS; Le Bihan T; Le Saëc P; Bris NL; Bailly C; Saï-Maurel C; Bourgeois M; Chérel M; Tripier R; Faivre-Chauvet A Bioconjug Chem; 2019 Sep; 30(9):2393-2403. PubMed ID: 31386357 [TBL] [Abstract][Full Text] [Related]
40. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]